Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

NCT05628740 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Chronic Cough

Interventions

DRUG: 3 mg NOC-100 (via nebulizer)
DRUG: 1 mg NOC-110 (via DPI) [1x 1 mg capsule]
DRUG: 3 mg NOC-110 (via DPI)
DRUG: Placebo (via DPI)
DRUG: 6 mg NOC-110 (via DPI)
DRUG: Placebo (via DPI) [2x Placebo capsules]

Sponsor

Nocion Therapeutics